PD-L1 Status in Refractory Lymphomas

Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various solid tumors. A remarkable improvement has also been observed in the treatment of patients with refractory/relapsing classical Hodgkin lymphoma (cHL). We investigated PD-L1 status in a variety of treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vranic, Semir, Ghosh, Nilanjan, Kimbrough, Jeffery, Bilalovic, Nurija, Bender, Ryan, Arguello, David, Veloso, Yvonne, Dizdarevic, Aida, Gatalica, Zoran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115714/
https://www.ncbi.nlm.nih.gov/pubmed/27861596
http://dx.doi.org/10.1371/journal.pone.0166266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115714/
https://www.ncbi.nlm.nih.gov/pubmed/27861596
http://dx.doi.org/10.1371/journal.pone.0166266

Ejemplares similares